Posted On: 09/09/2015 10:18:56 PM
Post# of 30038
Re: All Aboard #20172
If we just look at what has been publicly announced since then...
AUGUST 20, 2015 • 8:35 AM EDT
Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF
AUGUST 17, 2015 • 8:05 AM EDT
Amarantus Reports Second Quarter 2015 Financial Results and Business Overview
AUGUST 5, 2015 • 8:50 AM EDT
Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID
AUGUST 3, 2015 • 5:30 PM EDT
Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds
JULY 29, 2015 • 7:35 AM EDT
Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
JULY 27, 2015 • 7:35 AM EDT
Amarantus Diagnostics Establishes Strategic Advisory Committee
JULY 22, 2015 • 10:30 AM EDT
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)
JULY 20, 2015 • 7:05 AM EDT
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
JULY 15, 2015 • 7:05 AM EDT
Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns
JULY 13, 2015 • 7:05 AM EDT
Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS
JUNE 30, 2015 • 8:35 AM EDT
Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease
JUNE 15, 2015 • 7:05 AM EDT
Amarantus Announces Presentation of Eltoprazine Phase 1/2a Clinical Data at the 19th International Congress of Parkinson's Disease and Movement Disorders
JUNE 9, 2015 • 4:05 PM EDT
Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing
JUNE 9, 2015 • 10:58 AM EDT
Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test(R) Data at the 2015 Alzheimer's Association International Conference(R)
JUNE 5, 2015 • 7:35 AM EDT
Amarantus Opens First Clinical Trial Site and Commences Patient Enrollment for Lead Product Candidate Eltoprazine's Phase 2b Study in Parkinson's Disease Levodopa-Induced Dyskinesia
AUGUST 20, 2015 • 8:35 AM EDT
Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF
AUGUST 17, 2015 • 8:05 AM EDT
Amarantus Reports Second Quarter 2015 Financial Results and Business Overview
AUGUST 5, 2015 • 8:50 AM EDT
Amarantus Announces a New Eltoprazine Publication Confirming the Long-Term Efficacy and Elucidating the Mechanism of Action in PD-LID
AUGUST 3, 2015 • 5:30 PM EDT
Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds
JULY 29, 2015 • 7:35 AM EDT
Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
JULY 27, 2015 • 7:35 AM EDT
Amarantus Diagnostics Establishes Strategic Advisory Committee
JULY 22, 2015 • 10:30 AM EDT
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)
JULY 20, 2015 • 7:05 AM EDT
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
JULY 15, 2015 • 7:05 AM EDT
Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns
JULY 13, 2015 • 7:05 AM EDT
Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS
JUNE 30, 2015 • 8:35 AM EDT
Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease
JUNE 15, 2015 • 7:05 AM EDT
Amarantus Announces Presentation of Eltoprazine Phase 1/2a Clinical Data at the 19th International Congress of Parkinson's Disease and Movement Disorders
JUNE 9, 2015 • 4:05 PM EDT
Amarantus Completes Capital Restructuring in Preparation for National Exchange Listing
JUNE 9, 2015 • 10:58 AM EDT
Amarantus Diagnostics Announces Acceptance of Two Late-Breaking Abstracts on LymPro Test(R) Data at the 2015 Alzheimer's Association International Conference(R)
JUNE 5, 2015 • 7:35 AM EDT
Amarantus Opens First Clinical Trial Site and Commences Patient Enrollment for Lead Product Candidate Eltoprazine's Phase 2b Study in Parkinson's Disease Levodopa-Induced Dyskinesia
(0)
(0)Scroll down for more posts ▼
